Last week, we were honored to have National Organization for Rare Disorders (NORD) Chief Strategic and Operations Officer Kelly Esperias visit us in Carlsbad, where she presented Ionis with a #RareImpactAward. It’s always special to welcome our patient advocacy partners to our Carlsbad campus and share a behind-the-scenes look at the work driving progress for patient communities. We are grateful to work with such impactful organizations whose missions inspire us to keep advancing innovation for patients and their families.
Ionis Pharmaceuticals, Inc.
Biotechnology Research
Carlsbad, CA 87,855 followers
Building on our impossible firsts, we can change the course of human health.
About us
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
- Website
-
http://www.ionis.com
External link for Ionis Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Carlsbad, CA
- Type
- Public Company
- Founded
- 1989
- Specialties
- RNA-targeted medicines and RNA-targeted therapeutics
Locations
-
Primary
Get directions
2855 Gazelle Ct
Carlsbad, CA 92010, US
Employees at Ionis Pharmaceuticals, Inc.
-
Rick Buck
Say what you do. Do what you say. Make privacy a competitive advantage.
-
Renato Vasconcelos, Yale MBA, CPA, CISA, CFE
-
Neil Keene
Biotech Marketing Executive | Industry Speaker | Digital Transformation Thought Leader
-
Shay Bujanover MD, MBA
Healthcare Executive | Medical Strategy | Organizational Excellence | Cross-functional Collaboration
Updates
-
At Ionis, our work is more than just science, it’s about people. Behind every treatment we pursue is a commitment to delivering hope, care and impact. Learn more about how we're changing the course of human health through our dedicated efforts: https://ionis.com/
-
We are grateful to be part of the National Triglyceride Alliance. This was a great opportunity to connect in person while at ASPC 2025, and we are looking forward to what's next!
It was a privilege to connect in person with some of our valued member partners, Sponsors, and Scientific Advisory Committee members at the ASPC 2025 Congress on CVD Prevention in Boston. We're grateful for the shared commitment to advancing care, awareness, and education for severe hypertriglyceridemia (#sHTG). Looking forward to continuing the collaboration—and to the next time we’re together.
-
-
We’re proud to be recognized by the National Organization for Rare Disorders (NORD) with a #RareImpactAward for Industry Innovation, honoring our treatment for familial chylomicronemia syndrome (FCS). It was a true joy celebrating this achievement with colleagues who helped bring this medicine to the FCS community. The recognition reflects our unwavering commitment to advancing treatments for people living with serious diseases. Thank you to NORD for this honor!
-
-
Today we reported Q2 2025 financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our second quarter highlights: https://lnkd.in/eu36zPSt
-
-
Our teams have been hard at work this summer, collaborating with neurology communities across the country to listen and learn from them. Attending community and scientific events is an essential part of our efforts and, in the past few weeks, we have shared research, resources and offered support at the United Leukodystrophy Foundation (ULF) Scientific and Family Conference, CJD Foundation, Inc. Family Conference and the Angelman Syndrome Foundation and Dup15q Alliance Research Symposium, among many others. We leave these events energized to drive our research and clinical development programs on behalf of patients and caregivers. HCPs: looking to learn more about our commitment to advancing treatment options for serious neurologic diseases? Visit https://lnkd.in/eyN3n-6n
-
Finding community and a sense of purpose while #livingwithFCS (familial chylomicronemia syndrome) has provided Genevie hope as she navigates a new “normal.” Read about her experience: https://lnkd.in/e2n-Tegg
-
-
Today, the CHMP in the European Union recommended the approval of Ionis’ and Sobi - Swedish Orphan Biovitrum AB (publ)’s treatment for familial chylomicronemia syndrome (FCS). Read more about the news: https://lnkd.in/ezb4kMqS
-
-
From groundbreaking scientific discovery in our labs to strategic business planning for our future, our inclusive and caring teams drive innovation and excellence across every function of our company. Sound like a culture where you’d thrive? Join us: https://ionis.com/careers
-
Today, we announced the publication of Phase 3 data of our investigational medicine for the treatment of hereditary angioedema (#HAE) in The Journal of Allergy and Clinical Immunology (JACI) In Practice from American Academy of Allergy, Asthma and Immunology - AAAAI. #HAE is a genetic #raredisease characterized by unpredictable and potentially painful swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat. Learn more: https://lnkd.in/eT4_r_Wr
-